Blocking a specific enzyme to protect kidneys from cisplatin damage.
Inhibition of fatty acid amide hydrolase as a novel strategy to prevent nephrotoxicity of cisplatin.
This study is looking at whether blocking a specific enzyme can help protect your kidneys from damage caused by cisplatin, a chemotherapy drug used for cancer treatment, by understanding how certain compounds in your body can support kidney health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10684803 on NIH RePORTER |
What this research studies
This research investigates how inhibiting fatty acid amide hydrolase can help prevent kidney damage caused by cisplatin, a common chemotherapy drug used to treat various cancers. The study focuses on understanding the role of the endocannabinoid system in kidney health, particularly how certain compounds interact with cannabinoid receptors to mitigate nephrotoxicity. By exploring the metabolic enzymes involved in the endocannabinoid system, the research aims to identify new therapeutic strategies to protect patients' kidneys during cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving cisplatin as part of their treatment regimen.
Not a fit: Patients who are not undergoing cisplatin treatment or those with pre-existing severe kidney conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce kidney damage in patients undergoing cisplatin chemotherapy.
How similar studies have performed: Previous studies have shown promise in using endocannabinoid system modulation to protect against kidney damage, suggesting that this approach may be effective.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Li, Ningjun — Virginia Commonwealth University
- Study coordinator: Li, Ningjun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.